Urinebased Molecular Testing versus Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Scottsdale/Phoenix, Arizona: 23-008567
NCT ID: NCT06126796
Sponsor Protocol Number: MDT-CxB-01
About this study
The purpose of this study is to evaluate patient-reported preference for CxBladder Monitor compared to cystoscopy for patients on surveillance for NMIBC.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Male or female with a history of histologically confirmed stage 0 (Ta and/or CIS) nonmuscle invasive bladder cancer who have at least 9 months of disease-free survival from last recurrence.
- Able to provide urine for testing and comply with study protocol.
- Have an email address and be willing to complete surveys online.
Exclusion Criteria:
- History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma).
- Patients with predominant (> 50%) variant histology.
- Patients with a history of upper tract and/or urethral cancer.
- Patients with a history of T1 NMIBC.
- Women who are pregnant.
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 7/5//23. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Scottsdale/Phoenix, Ariz.
Mayo Clinic principal investigator Mark Tyson, M.D., M.P.H. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available